Skip to main content

Table 5 Univariable and multivariable analysis of factors associated with response to etanercept for extended and persistant oligoarticular JIA

From: Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

Baseline characteristics Poor vs Intermediate and Excellent Responders Excellent vs Intermediate and Poor Responders
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Extended oligoarticular JIA
 Demographic
  Disease duration before start of etanercept 0.449 (0.146-1.144) 0.114 1.066 (0.184-7.261) 0.942 1.729 (0.723-4.87) 0.245 6.808 (1.520-63.332) 0.036
  Age of disease onset 0.561 (0.195-1.363) 0.213    2.091 (0.788-9.563) 0.218 3.447 (1.106-15.630) 0.053
 Disease activity
  VAS disease activity by physician at start of etanercept 0.361 (0.1-0.98) 0.07 0.841 (0.173-3.997) 0.816 1.271 (0.543-3.149) 0.582   
  Pain joint count 0.838 (0.333-2.186) 0.695    0.668 (0.242-1.577) 0.373 0.340 (0.070-1.097) 0.104
 Previous therapy
  No. of DMARDs used before start of etanercept 0.533 (0.19-1.343) 0.198 0.518 (0.087-2.841) 0.431 1.064 (0.449-2.613) 0.885   
  Fact of biologics using before start of etanercept 0.497 (0.188-1.193) 0.123 0.440 (0.138-1.337) 0.136 1.794 (0.729-6.57) 0.253   
Persistant oligoarticular JIA
 Demographic
  Disease duration before start of etanercept 0.671 (0.385-1.216) 0.157 1.118 (0.522-2.736) 0.785 1.154 (0.731-1.807) 0.527   
 Disease activity
  Morning stiffness, min 0.746 (0.429-1.391) 0.302    1.386 (0.886-2.25) 0.16 1.448 (0.902-2.413) 0.129
 Previous therapy
  Oral corticosteroids before start of etanercept 0.681 (0.389-1.095) 0.093 0.927 (0.482-5.718) 0.858 0.768 (0.149-1.297) 0.487   
  No. of DMARDs used before start of etanercept 0.633 (0.343-1.171) 0.131 0.562 (0.250-1.232) 0.145 1.629 (1.025-2.748) 0.049 1.691 (1.04-2.958) 0.046
 Background therapy
  Concomitant NSAID at start of etanercept 0.838 (0.408-1.637) 0.609    0.711 (0.445-1.12) 0.145 0.649 (0.388-1.058) 0.089
 Laboratory tests
  CRP at start of etanercept 0.869 (0.515-1.791) 0.635    1.3 (0.833-2.099) 0.247 1.385 (0.874:2.274) 0.164
  1. CHAQ child health assessment questionnaire, CI confidence interval, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, JIA juvenile idiopathic arthritis, VAS visual analog scale
  2. All entries in italic are statistically significant